ROTE WILLIAM E. 4
4 · Travere Therapeutics, Inc. · Filed Feb 4, 2025
Insider Transaction Report
Form 4
ROTE WILLIAM E.
Chief Research Officer
Transactions
- Award
Employee stock option (right to buy)
2025-01-31+58,000→ 58,000 totalExercise: $20.46Exp: 2035-01-31→ Common Stock (58,000 underlying) - Award
Common Stock
2025-01-31+21,500→ 104,670 total - Sale
Common Stock
2025-02-03$19.78/sh−8,951$177,051→ 95,719 total
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
- [F2]This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
- [F3]One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.